Investigation of structure-activity relationships of oxyntomodulin (Oxm) using oxm analogs

Endocrinology

Volumn 150, Issue 4, 2009, Pages 1712-1721

  Druce, Maralyn R ^a   Minnion, James S ^a   Field, Benjamin C T ^a   Patel, Sejal R ^a   Shillito, Joyceline C ^a   Tilby, Michael ^a   Beale, Kylie E L ^a   Murphy, Kevin G ^a   Ghatei, Mohammad A ^a   Bloom, Stephen R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; DIPEPTIDYL PEPTIDASE IV; DRUG ANALOG; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; OCTAPEPTIDE; OXYNTOMODULIN; OXYNTOMODULIN DERIVATIVE; OXYNTOMODULIN[30-37]; PROTEINASE; UNCLASSIFIED DRUG; VALINE PYRROLIDIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DESIGN; DRUG STRUCTURE; ENZYME DEGRADATION; FOOD INTAKE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NAUSEA; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; EATING; MALE; MICE; MOLECULAR SEQUENCE DATA; OXYNTOMODULIN; PROTEIN BINDING; RATS; RECEPTORS, GLUCAGON; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 63849300305     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0828     Document Type: Article

References (57)

1. Dubrasquet M, Bataille D, Gespach C 1982 Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep 2:391-395
2. Jarrousse C, Audousset-Puech MP, Dubrasquet M, Niel H, Martinez J, Bataille D 1985 Oxyntomodulin (glucagon-37) and its C-terminal octapeptide inhibit gastric acid secretion. FEBS Lett 188:81-84
3. Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ, Christiansen J 1988 Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 18:499-503
4. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR 2001 Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244-4250
5. Gros L, Thorens B, Bataille D, Kervran A 1993 Glucagon-like peptide-1-(7- 36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 133:631-638
6. Schepp W, Dehne K, Riedel T, Schmidtler J, Schaffer K, Classen M 1996 Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2. Digestion 57:398-405
7. Baggio LL, Huang Q, Brown TJ, Drucker DJ 2004 Oxyntomodulin and glu- cagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546 -558
8. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR 2004 Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695
9. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D 2005 Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 7:467-477
10. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR 2003 Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696 -4701
11. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR 2005 Subcutaneous oxyntomodu- lin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54:2390-2395
12. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR 2006 Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30:1729 -1736
13. Dakn CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR 2002 Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283:E1173-E1177
14. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M 2001 Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530 -2539
15. Hruby VJ, Agnes RS, CaiC 2002 Design of peptide agonists. Methods Enzymol 343:73-91
16. Garber AJ 2005 Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management. Diabetes Obes Metab 7:666 -674
17. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9 -24
18. Deacon CF, Johnsen AH, Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
19. Kieffer TJ, McIntosh CH, Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
20. Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FP, Flatt PR 2004 N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 180:379 -388
21. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ 1998 Dipep- tidyl peptidaseIV resistantanalogues of glucagon-likepeptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278
22. Hinke SA, Manhart S, Kuhn-Wache K, Nian C, Demuth HU, Pederson RA, Mcintosh CH 2004 [Ser2]- and [SerP2] incretin analogs: comparison of dipep- tidyl peptidase IV resistance and biological activities in vitro and in vivo. J Biol Chem 279:3998 -4006
23. O'Harte FP, Mooney MH, Lawlor A, Flatt PR 2000 N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim Biophys Acta 1474:13-22
24. Hupe-Sodmann K, Goke R, Goke B, Thole HH, Zimmermann B, Voigt K, McGregor GP 1997 Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides 18:625-632
25. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole H, Zimmermann B, Voigt K 1995 Characterisation of the processing by human neutralendopeptidase24.11 ofGLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149 -156
26. Thornton K, Gorenstein DG 1994 Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 33:3532-3539
27. Al Sabah S, Donnelly D 2004 The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists. Protein Pept Lett 11:9 -14
28. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O 1994 Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269:6275-6278
29. Xiao Q, Giguere J, Parisien M, Jeng W, St Pierre SA, Brubaker PL, Wheeler MB 2001 Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40:2860 -2869
30. Bataille D, Gespach C, Coudray AM, Rosselin G 1981 "Enterolglucagon": a specific effect on gastric glands isolated from the rat fundus. Evidence for an "oxyntomodulin" action. Biosci Rep 1:151-155
31. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV 1988 Oxynto- modulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 21:151-166
32. Moens K, Flamez D, Van Schravendijk C, Ling Z, Pipeleers D, Schuit F 1998 Dual glucagon recognition by pancreatic β-cells via glucagon and glucagon- like peptide 1 receptors. Diabetes 47:66 -72
33. Atherton E, Fox H, Harkiss D, Logan CJ, Sheppard RC, Williams BJ 1978 A mild procedure for solid phase synthesis: use of fluorenylmethoxycarbon- ylamino-acids. J Chem Soc Chem Commun 537-539
34. Wellings DA, Atherton E 1997 Standard Fmoc protocols. Methods Enzymol 289:44-67
35. Pennington MW, Dunn BM 1994 Peptide synthesis protocols. Totowa, NJ: Humana Press
36. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H 2000 Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once dailyadministration. J Med Chem 43:1664 -1669
37. Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH, Bell JD, Dhillo WS, Stanley SA, Ghatei MA, Bloom SR 2006 Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Bio- chem Biophys Res Commun 350:298 -306
38. Bhogal R, Smith DM, Purkiss P, Bloom SR 1993 Molecular identification of binding sites for calcitonin gene-related peptide (CGRP) and islet amyloid polypeptide (IAPP) in mammalian lung: species variation and binding of truncated CGRP and IAPP. Endocrinology 133:2351-2361
39. BoltonAE,HunterWM1973 The labelling of proteins to high specific radioactivities by conjugation to a 125I-containingacylating agent. Biochem J133:529-539
40. Lachey JL, D'Alessio DA, Rinaman L, Elmquist JK, Drucker DJ, Seeley RJ 2005 The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology146:458 -462
41. Cannon CM, Scannell CA, Palmiter RD 2005 Mice lacking dopamine D1 receptors express normal lithium chloride-induced conditioned taste aversion for salt but not sucrose. Eur J Neurosci 21:2600 -2604
42. Umezawa H, Aoyagi T, Ogawa K, Naganawa H, Hamada M, Takeuchi T 1984 Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. J Antibiot (Tokyo) 37:422-425
43. Rahfeld J, Schierhorn M, Hartrodt B, Neubert K, Heins J 1991 Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipep- tidyl peptidase IV? Biochim Biophys Acta 1076:314-316
44. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS, Holst JJ 2000 Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-likepeptide-2 inratsandmice. Endocrinology141:4013-4020
45. Siegel EG, Scharf G, Gallwitz B, Mentlein R, Morys-Wortmann C, Folsch UR, Schmidt WE 1999 Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur J Clin Invest 29:610 -614
46. Thum A, Hupe-Sodmann K, Goke R, Voigt K, Goke B, McGregor GP 2002 Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 110:113-118
47. Kurtzhals P, HavelundS, JonassenI, Kiehr B, Larsen UD, Ribel U, Markussen J 1995 Albumin binding of insulins acylated with fattyacids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312(Pt 3):725-731
48. Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR 2004 Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-sub-stituted GLP-1 analogues. Biol Chem 385:169 -177
49. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha RR 2003 The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitaryadenylate cyclase activating polypeptide-(1-38). J Biol Chem 278:22418 -22423
50. Rahfeld J, Schutkowski M, Faust J, Neubert K, BarthA, Heins J 1991 Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney. Biol Chem Hoppe Seyler 372:313-318
51. Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM 2003 The importance of the nine-amino acid C-terminal sequence ofexendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 114:153-158
52. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161
53. Deacon CF 2005 What do we know about the secretion and degradation of incretin hormones? Regul Pept 128:117-124
54. Carles-Bonnet C, Martinez J, Jarrousse C, Aumelas A, Niel H, Bataille D 1996 H-Lys-Arg-Asn-Lys-Asn-Asn-OH is the minimal active structure of oxynto- modulin. Peptides 17:557-561
55. Jarrousse C, Carles-Bonnet C, Niel H, Sabatier R, Audousset-Puech MP, Bla- che P, Kervran A, Martinez J, Bataille D 1993 Inhibition of gastric acid secretion by oxyntomodulin and its 19 -37 fragment in the conscious rat. Am J Physiol 264(5 Pt 1):G816 -G823
56. Greenough A, Cole G, Lewis J, Lockton A, Blundell J 1998 Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion. Physiol Behav 65:303-310
57. Chelikani PK, Haver AC, Reidelberger RD 2006 Dose-dependent effects of pep- tide YY(3-36) on conditioned taste aversion in rats. Peptides 27:3193-3201